Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.

The global Signifor market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Signifor volume and value at global level, regional level and company level. From a global perspective, this report represents overall Signifor market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Signifor in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Signifor manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novartis
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
0.3mg/ml
0.6mg/ml
0.9mg/ml

Segment by Application
Hospital
Pharmacy